Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Phase 4Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 4 trial of guselkumab in psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Aug 2021; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04929210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929210.